Drug Reduces Risk of Early Menopause in Chemotherapy PatientsThe Breast Cancer Site
A study published in the New England Journal of Medicine on March 4, 2015, found that women who took goserelin (brand name Zoladex) while receiving chemotherapy treatment had improved ovary functioning, higher pregnancy rates and increased survival time.
The participants included 257 women with operable hormone-receptor-negative breast cancer. All received chemotherapy and half also took goserelin. Two years later, researchers measured the women's ovarian failure, or the absence of menses in the past six months along with their levels of follicle-stimulating hormones. A total of 218 of the women were evaluated and 135 had a complete set of data available for use.
The rate of ovarian failure in the group who took goserelin was 8 percent. Women who did not take the drug and only received chemotherapy had a 22 percent rate of ovarian failure. The patients who took goserelin were also more likely to become pregnant, 21 percent conceived, whereas 11 percent of the chemo-only group became pregnant. Another factor that was affected was the women's overall disease-free survival rate. After four years, the overall survival rate of the goserelin group was 92 percent while the chemotherapy group standard was 82 percent.
Goserelin is a man-made hormone that over stimulates the body's natural production of hormones and causes it to shut down temporarily. It is an injection given at one month intervals. The drug is commonly used to treat men with prostate cancer and women with endometriosis or who are going to have an endometrial ablation. Side effects of goserelin include loss of bone mineral density, increased risk of osteoporosis, problems with urination, trouble breathing, nausea, loss of appetite and high blood sugar. Women who take this medicine may feel menopausal symptoms like hot flashes, insomnia, mood changes and vaginal dryness.